Lindus Therapeutics

Lindus Therapeutics is a next-generation drug development company. We advance portfolios of in-licensed assets, pairing our own asset identification and selection capability with an integrated clinical trial execution platform. Domain experts work hand in glove with proprietary AI systems, so we and our partners reach value inflection points faster and more efficiently than the industry standard. Lindus is backed by investors and advisors including Peter Thiel and Bob Langer. Lindus has delivered over 45 trials across cardiometabolic, respiratory, psychiatry, dermatology, women's health, and diagnostics. In trials where Lindus owned enrollment, 82% completed on or ahead of the timeline presented at proposal. Milestone-based payments align incentives around timelines and budgets. The company is backed by leading investors and advisors, including Peter Thiel and Prof. Robert S. Langer.